Abstract 3973: Diffusion-weighted imaging of bone metastases as treatment response biomarker in prostate cancer

INTRODUCTION: Response assessment of bone metastases (BM) remains a challenge for drug development in metastatic castration resistant prostate cancer (mCRPC) as standard imaging techniques, computed tomography and bone scintigraphy, fail to characterize BM. Diffusion-weighted imaging (DWI) is a func...

Full description

Saved in:
Bibliographic Details
Published in:Cancer research (Chicago, Ill.) Ill.), 2016-07, Vol.76 (14_Supplement), p.3973-3973
Main Authors: Perez-Lopez, Raquel, Blackledge, Matthew D., Mossop, Helen, Mateo, Joaquin, Collins, David, Morgan, Veronica A., McDonald, Alison, Sandhu, Shahneen, Omlin, Aurelius, Bianchini, Diletta, Zafeiriou, Zafeiris, Rescigno, Pasquale, Kolinsky, Michael, Nava Rodrigues, Daniel, Flohr, Penny, Ebbs, Berni, Fowler, Gemma, Porta, Nuria, Hall, Emma, Leach, Martin, de Bono, Johann S., Koh, Dow-Mu, Tunariu, Nina
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:INTRODUCTION: Response assessment of bone metastases (BM) remains a challenge for drug development in metastatic castration resistant prostate cancer (mCRPC) as standard imaging techniques, computed tomography and bone scintigraphy, fail to characterize BM. Diffusion-weighted imaging (DWI) is a functional MRI technique that studies the motion of water molecules within a tissue informing on cellularity. We hypothesized that changes in whole body (WB) DWI informs on BM response to treatment in mCRPC. METHODS: We conducted a phase II trial of the PARP inhibitor olaparib in mCRPC (TOPARP-A; CRUK/11/029); the primary endpoint was response rate defined using RECIST 1.1, PSA falls of ≥50% and conversion of circulating tumour cell (CTC) counts from ≥5 to
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2016-3973